Evaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal Function
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
- To determine and compare the pharmacokinetics (PK) of a single dose of 25 mg Androxal in
overweight male subjects with various stages of renal impairment and in volunteers with
normal renal function.
- To compare the safety profile of a single dose of 25 mg Androxal in overweight male
subjects with various stages of renal impairment and in volunteers with normal renal
function.